Document:

Unassociated Document

    

      Exhibit
10.22

       

      SECOND
AMENDMENT AGREEMENT

      

      This
Agreement dated as of October 31 2010 among ASIA CORK INC. (formerly, HANKERSEN
INTERNATIONAL CORP.,) a Delaware corporation (together with its successors and
assigns, the “Company”), and the
investor identified on the signature page hereto (the “Investor”.

       

      WHEREAS, the Company and
certain investors (the “Investors”) executed a certain securities purchase
agreement dated May 29, 2008 (as amended, the “SPA”);

       

      WHEREAS, pursuant to the SPA
the aggregate Investment Amount (as defined in the SPA) is $700,000 and the
Company issued a Promissory Note (“Note”) and Warrant to each
Investor;

       

      WHEREAS,  the
Company has filed a registration statement on form S-1 (the “Registration
Statement”) with the Securities and Exchange Commission with respect to a
primary offering by the Company of securities (the “Offering”).

       

      WHEREAS,  the
Company and the Investors executed an Amendment Agreement as of July 6, 2010
with respect to the parties rights and obligations under the SPA, the Notes and
the Warrants, which Amendment Agreement contains provisions which included (i)
an extension of the Maturity Date until October 31, 2010, (ii) the agreement of
the Company and the Investors that upon the closing of the Offering, the
Investors would  (A) receive cash in an amount equal to 50% of the
outstanding principal amount of the Notes upon the closing of the Offering and
(B) convert the balance of the Notes into a whole number of Securities that is
equal to the quotient of the sum of (A) 50% of the outstanding principal amount
of the Notes and (B) all accrued and unpaid interest thereon, divided by fifty
percent (50%) of the Financing Based Conversion Price and (iii) the agreement of
the Investors to not sell or otherwise transfer any shares of Common Stock for a
period of nine (9) months after the Offering.

       

      WHEREAS, since the
Registration Statement has not yet been declared effective by the Securities and
Exchange Commission, the parties to the SPA desire to extend the maturity date
of the Notes.

       

      NOW, THEREFORE, in
consideration of the mutual covenants contained in this Agreement, and for other
good and valuable consideration the receipt and adequacy of which are hereby
acknowledged, the Company and the Investor agrees as follows:

       

      
        	
                 
      

              	
                1.

              	
                Note.  The
      Note is hereby amended as follows:

              

      

       

      
        	
                 
      

              	
                a.

              	
                The
      Maturity Date shall be February 28
2011

              

      

       

      b.   The
interest rate under the Notes shall be 18% per annum from the date of issuance
through the Maturity Date.       In the event
that the closing of the Offering shall not occur by February 28, 2011, the
interest rate under the Note shall be 24% per annum, accruing from the first
anniversary of the issuance of the Note.

       

      
        
           

        

        
          1

          
            

          

        

        
           

        

      

       

      2.      Default Any defaults
by the Company pursuant to the SPA or the Notes prior to the date hereof shall
be deemed waived provided that, and so long as, the Company complies with the
terms of theNote, as amended.

       

      3.      Miscellaneous

       

      
        	
                 
      

              	
                a.

              	
                Entire
      Agreement. This Agreement shall only serve as an Amendment to the
      Note with regard to the specific terms acknowledged in Section 1a and 1b
      of this Agreement. All other terms previously agree upon by the parties in
      the Amendment Agreement dated July 6, 2010 shall remain in full force and
      effect. This Agreement, together with the Amendment Agreement, the Notes
      and the Warrants, contain the entire understanding of the parties with
      respect to the subject matter hereof and supersede all prior agreements,
      understandings, discussions and representations, oral or written, with
      respect to such matters, which the parties acknowledge have been merged
      into such documents.

              

      

       

      
        	
                 
      

              	
                b.

              	
                Document
      References.     The provisions of the SPA,
      the Notes and the Warrants as may be hereby amended, that do not conflict
      with this Agreement shall remain the same and in full force and effect.
      All capitalized terms used herein, unless otherwise defined, shall have
      the meanings ascribed to them under the
Note.

              

      

       

      
        	
                 
      

              	
                c.

              	
                Notices.  Any
      and all notices or other communications or deliveries required or
      permitted to be provided hereunder shall be delivered in accordance with
      the SPA

              

      

       

      
        	
                 
      

              	
                d.

              	
                Amendments; Waivers;
      No Additional Consideration.  No provision of this
      Agreement may be waived or amended except in a written instrument signed
      by the Company and the Investors holding at least a majority in interest
      of the outstanding aggregate principal amount of the Notes.  No
      waiver of any default with respect to any provision, condition or
      requirement of this Agreement shall be deemed to be a continuing waiver in
      the future or a waiver of any subsequent default or a waiver of any other
      provision, condition or requirement hereof, nor shall any delay or
      omission of either party to exercise any right hereunder in any manner
      impair the exercise of any such
right.

              

      

       

      
        	
                 
      

              	
                e.

              	
                Successors and
      Assigns.  This Agreement shall be binding upon and inure
      to the benefit of the parties and their successors and permitted
      assigns.

              

      

       

      
        	
                 
      

              	
                f.

              	
                No Third-Party
      Beneficiaries. This Agreement is intended for the benefit of the
      parties hereto and their respective successors and permitted assigns and
      is not for the benefit of, nor may any provision hereof be enforced by,
      any other Person.

              

      

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

       

      
        	
                 
      

              	
                g.

              	
                Governing
      Law.  This Agreement shall be governed by and be
      construed in accordance with the laws of the State of New York without
      regard to the conflicts of law rules of such state.  Each of the
      Company and the Investors hereby irrevocably and unconditionally submits,
      for itself and its property, to the jurisdiction of the Supreme Court of
      the State of New York sitting in New York County and of the United States
      District Court for the Southern District of New York, and any appellate
      court from any thereof, in respect of actions brought against it as a
      defendant, in any action, suit or proceeding arising out of or relating to
      this Agreement, or for recognition or enforcement of any judgment, and
      each of the parties hereto hereby irrevocably and unconditionally agrees
      that all claims in respect of any such action, suit or proceeding may be
      heard and determined in such courts.  Each of the parties hereto
      agrees that a final judgment in any such action, suit or proceeding shall
      be conclusive and may be enforced in other jurisdictions by suit on the
      judgment or in any other manner provided by law. The Company and the
      Investors hereto irrevocably and unconditionally waives, to the fullest
      extent it may legally and effectively do so, any objection which it may
      now or hereafter have to the laying of venue of any action, suit or
      proceeding arising out of or relating to this Agreement, or in any court
      referred to above.  Each of the parties hereby irrevocably
      waives, to the fullest extent permitted by law, the defense of an
      inconvenient forum to the maintenance of such action, suit proceeding in
      any such court and waives any other right to which it may be entitled on
      account of its place of residence or
domicile.

              

      

       

      
        	
                 
      

              	
                h.

              	
                Execution.  This
      Agreement may be executed in two or more counterparts, all of which when
      taken together shall be considered one and the same agreement and shall
      become effective when counterparts have been signed by each party and
      delivered to the other party, it being understood that both parties need
      not sign the same counterpart.

              

      

       

      
        	
                 
      

              	
                i.

              	
                Severability.  If
      any provision of this Agreement is held to be invalid or unenforceable in
      any respect, the validity and enforceability of the remaining terms and
      provisions of this Agreement shall not in any way be affected or impaired
      thereby and the parties will attempt to agree upon a valid and enforceable
      provision that is a reasonable substitute therefor, and upon so agreeing,
      shall incorporate such substitute provision in this
    Agreement.

              

      

       

      
        	
                 
      

              	
                j.

              	
                Independent Nature of
      Investors’ Obligations and Rights.  The obligations of
      each Investor hereunder are several and not joint with the obligations of
      any other Investor, and no Investor shall be responsible in any way for
      the performance of the obligations of any other Investor
      hereunder.  The decision of each Investor to purchase Securities
      pursuant hereto has been made by such Investor independently of any other
      Investor.

              

      

       

      [Signature
Page Follows]

       

      
        
           

        

        
          3

          
            

          

        

        
           

        

      

       

      IN
WITNESS WHEREOF, the parties hereto have caused this Addendum to be duly
executed by their respective authorized signatories as of the date first
indicated above.

      
      

      
        
          
            
              	 
      	
                      Asia
      Cork Inc.

                    
	 
      	 
      
	 
      	
                      By: 

                    	
                      /s/Pengcheng
      Chen

                    
	 
      	
                      Name:  Pengcheng
      Chen

                    
	 
      	
                      Title:
      President

                    

            

          

        

      

      

      [Remainder
of Page Intentionally Left Blank; Signature Page for Investors
Follows]

       

      
        
           

        

        
          4

          
            

          

        

        
           

        

      

      IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed by their respective authorized signatories as of the date first
indicated above.

       

      
        
          
            	 
      	
                    NAME
      OF INVESTOR

                  
	 
      	 
      
	 
      	
                    IDAHOCORK,
      LLC

                  
	 
      	 
      
	 
      	
                    By: 

                  	/s/
      Gary Hawkins
	 
      	 
      	
                    Name:
      Gary Hawkins

                  
	 
      	 
      	
                    Title: 
      Manager

                  

          

        

      

       

      
        
           

        

        
          5

          
            

          

        

        
           

        

      

       

      IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed by their respective authorized signatories as of the date first
indicated above.

       

      
        
          
            	 
      	
                    ANCORA
      GREATER CHINA FUND, LP

                  
	 
      	 
      	 
      
	 
      	
                    By: 

                  	/s/
      Jon Mickitsch
	 
      	 
      	
                    Name:
      Jon Mickitsch

                  

          

        

      

      
        
           

        

        
          6

          
            

          

        

        
           

        

      

      IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed by their respective authorized signatories as of the date first
indicated above.

       

      
        
          
            
              	 
      	
                      PIPE
      EQUITY PARTNERS, LLC

                    
	 
      	 
      	 
      
	 
      	
                      By: 

                    	/s/
      Greg Freihofner
	 
      	 
      	
                      Name:
      Greg Freihofner

                    
	 
      	 
      	
                      Title: 
      Managing
Partner

                    

            

          

        

      

      
        
           

        

        
          7

          
            

          

        

        
           

        

      

       

      IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed by their respective authorized signatories as of the date first
indicated above.

       

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            	 
      	
                                    NAME
      OF INVESTOR

                                  
	 
      	 
      
	 
      	
                                    SILVER
      ROCK II LTD.

                                  
	 
      	 
      
	 
      	
                                    By: 

                                  	Rima
      Salam
	 
      	 
      
	 
      	
                                    Name:    Rima
      Salam

                                  
	 
      	 
      
	 
      	 
      

                          

                        

                      

                    

                  

                

              

            

          

        

      

      
        

          
            
               

            

            
              8Unassociated Document

     

    
      Exhibit
10.1

         

    

    RESEARCH/MANUFACTURING
AGREEMENT

    

    THIS
RESEARCH/MANUFACTURING AGREEMENT (“Agreement”), effective as of the last date of
signature by the parties below (“Effective Date”), is by and between Schering
Corporation, acting through its Schering-Plough Research Institute division,
2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0539 (hereinafter
“SPRI”); and Albany Molecular Research, Inc., 21 Corporate Circle, Albany, New
York 12203-5154 (together with its subsidiaries and affiliates hereinafter
collectively referred to as “AMRI”).

    

    WHEREAS,
SPRI is engaged in the development of pharmaceutical products; and,

    

    WHEREAS,
AMRI is engaged in the business of providing synthetic chemical research and
analysis, chemistry consulting, medicinal chemical synthesis, computational
chemistry services, manufacturing of specialty chemical products, process
development, cGMP synthesis, analytical method development, validation and
release testing, stability studies, and related services, and undertakes such as
an independent company, understanding that neither AMRI nor its employees nor
agents shall be considered an employee of SPRI; nor a participant in any
programs, insurance or other benefits extended to SPRI’s employees;
and,

    

    WHEREAS,
AMRI hereby represents and warrants to SPRI that this undertaking does not
conflict with its duties and obligations under any other agreement to which it
is a party, including any agreement with any other company or institution or any
policies applicable to them; and,

    

    WHEREAS,
SPRI proposes to engage AMRI for the specific purpose of providing chemical
research, analysis, manufacturing of specialty chemical products or related
services which AMRI may offer on a project-by-project basis.

    

    NOW,
THEREFORE, IT IS AGREED AS FOLLOWS:

    

    
      	
              A.

            	
              AMRI
      Services:

            

    

     

    
      	
               
      

            	
              1.

            	
              SPRI may engage AMRI to perform chemistry
      services, which may include consulting, chemical synthesis, chemical
      process research, analytical methods development, validation or release
      testing, and other related services
      (collectively, the “Services”) in connection with one or more projects
      (each a “Project” and collectively, the “Projects”) during the Term (as
      hereinafter defined) as mutually agreed by the Parties from time to time
      pursuant to one or more written Research Project Appendices in the form of
      Appendix 1 attached hereto (each a “Research Project Appendix” and
      collectively, the “Research Project Appendices”).  AMRI shall
      not commence work on any Project or provide any Services until the parties
      enter into a Research Project Appendix, which will set forth (i) the
      Services to be performed by AMRI (including deliverables to be provided to
      SPRI in connection therewith), (ii) the timing for the Project (including
      relevant deadlines and delivery dates for deliverables), (iii) the cost
      and payment schedule with respect to such Services, (iv) any individuals
      designated to have management responsibility for the Project or otherwise
      required to perform the Services, and (v) to the extent necessary and
      appropriate, additional provisions applicable to the Services to be
      provided pursuant to the Research Project Appendix which shall not be
      inconsistent with the terms of this Agreement and which are not otherwise
      set forth in this Agreement.  Any terms or conditions included
      in a Research Project Appendix other than those described in this Section
      A.1. shall be deemed to conflict with this Agreement and shall have no
      force or effect.  References in this Agreement to this
      “Agreement” shall be deemed to include any Research Project Appendix
      entered into pursuant hereto, subject to the preceding
      sentence.  The parties expressly agree that the terms hereof
      cannot be altered by course of
dealings.

            

    

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    
      	
               
      

            	
              2.

            	
              Anything to the contrary contained in this
      Agreement notwithstanding, AMRI acknowledges and agrees that there is no
      minimum number of Projects for which SPRI is obligated to engage the
      services of AMRI and this Agreement shall not be construed as limiting in
      any way SPRI’s right to contract for any services with any other
      party.

            

    

     

    
      	
               
      

            	
              3.

            	
              In no event shall this Agreement be construed as
      obligating SPRI to pay any amounts for Services performed under this
      Agreement unless (i) SPRI actually engages AMRI to perform Services
      pursuant to this Agreement, (ii) such engagement is evidenced by a
      Research Project Appendix in the form of Appendix 1 entered into pursuant
      to this Agreement by the parties prior to the commencement of any such
      engagement, and (iii) AMRI complies with the procedures set forth in
      Section F.2. herein.  AMRI acknowledges and agrees that verbal
      authorization or instructions from SPRI or any of its affiliates to
      commence work or Services shall not be sufficient and shall have no force
      or effect and that any work or Services performed by AMRI prior to
      execution by the parties of a Research Project Appendix for the engagement
      shall be at the sole risk and expense of AMRI.  The parties
      expressly agree that this provision cannot be altered by course of
      dealings.

            

    

    

    
      	
               
      

            	
              4.

            	
              SPRI will define and the parties shall
      mutually agree upon the parameter of the Projects and define the time
      frame in which the Services are to be
      provided as requested.  Such Projects shall include, but not be
      limited to, the following:

            

    

    

    
      	
               
      

            	
              a)

            	
              Product Development
      Assistance:  AMRI shall be available to SPRI to advise on
      design and synthesis of organic compounds, to perform process chemistry
      and analytical services, and/or to complete the manufacture of organic
      compounds, subject to mutually acceptable Research Project Appendices
      governing the requested projects.  Such Research Project
      Appendices will specify the work to be undertaken, the conditions and
      timing under which work is to be completed, and the amount of AMRI’s
      compensation.

            

    

    

    
      	
               
      

            	
              b)

            	
              Technical
      Assistance:  AMRI shall be available to SPRI to perform
      synthetic chemical research, medicinal chemistry, process development, and
      process optimization studies.  The chemistry and scope of work
      is to be defined under mutual agreement between AMRI and
    SPRI.

            

    

    

    
      	
               
      

            	
              c)

            	
              Technical
      Consultations:  AMRI shall be available to SPRI at such
      times as are requested by SPRI for technical consultations with SPRI’s
      Research and Development personnel via telephone.  AMRI shall be
      available for consultation at mutually agreed upon sites, provided that
      the extent of this activity will be set by mutual agreement of SPRI and
      AMRI.  SPRI shall reimburse AMRI for [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/]

            

    

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    
      [CONFIDENTIAL TREATMENT REQUESTED BY AMRI –
01].

    

    

    
      	
              B.

            	
              Specific Duties of
      AMRI:

            

    

    

    
      	
               
      

            	
              1.

            	
              In
      assuming responsibility for undertaking this Agreement, AMRI
      will:

            

    

    

    
      	
               
      

            	
              a)

            	
              Perform
      chemistry consulting, computational services, synthetic chemical research,
      medicinal chemistry, process development and process optimization studies,
      and manufacturing of specialty chemicals for any Projects entered
      into.

            

    

    

    
      	
               
      

            	
              b)

            	
              Provide
      technical consultation, technical assistance and product development
      assistance, as defined, for any Projects entered
  into.

            

    

    

    
      	
               
      

            	
              c)

            	
              Develop
      or utilize existing analytical methods which will allow determination of
      the identity and quantification of the purity of any compounds
      delivered.

            

    

    

    
      	
               
      

            	
              d)

            	
              Provide
      Services and/or compounds as
      expeditiously as possible.

            

    

    

    
      	
               
      

            	
              e)

            	
              Provide
      to SPRI Certificates of Analysis to include, as appropriate, elemental
      analysis, optical rotation, HPLC analysis, NMR spectra, and an IR spectrum
      on any compounds provided.

            

    

    

    
      	
               
      

            	
              f)

            	
              Perform
      experiments using standard and accepted good laboratory practices and
      current Good Manufacturing Practices, techniques, and record keeping
      procedures, as appropriate to each
project.

            

    

    

    
      	
               
      

            	
              g)

            	
              Interact
      with SPRI’s scientists as is deemed appropriate in the conduct of a fully
      integrated drug discovery project team
effort.

            

    

    

    
      	
               
      

            	
              h)

            	
              Interact
      with and communicate with SPRI, to its satisfaction, and upon all
      requests, regarding any Projects.

            

    

    

    
      	
               
      

            	
              i)

            	
              Provide
      written research reports to SPRI describing the results and including full
      experimental procedures, due upon mutually agreed upon interim dates and
      upon the completion of individual
Projects.

            

    

    

    
      	
               
      

            	
              j)

            	
              Retain
      experimental records and laboratory notebooks containing experimental
      descriptions and data generated from this work for a period of seven (7)
      years.  After this time and on request by SPRI, AMRI shall
      provide to SPRI all experimental records and laboratory notebooks, or
      copies thereof, containing information from the Projects for retention in
      SPRI’s archives.

            

    

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    
      	
              C.

            	
              SPRI’s
      Obligations:  SPRI will:

            

    

    

    
      	
               
      

            	
              1.

            	
              Provide
      research samples, chromatographic information, and appropriate structural
      characterization spectra of relevant compounds to AMRI, as agreed to by
      SPRI.

            

    

    

    
      	
               
      

            	
              2.

            	
              Provide
      intermediates to AMRI where (and if) AMRI and SPRI mutually agree to be
      appropriate for project conduct and
completion.

            

    

    

    
      	
               
      

            	
              3.

            	
              Agree
      to pay AMRI for the Services to be performed by AMRI as set forth in
      Section F.2. herein and agreed upon in the applicable Research Project
      Appendix.

            

    

    

    
      	
              D.

            	
              Confidentiality:

            

    

    

    
      	
               
      

            	
              1.

            	
              With
      respect to any and all information indicated as being or which reasonably
      appears to be or is marked to be confidential, including, but not limited
      to, chemical synthesis or process data, proprietary chemicals, preclinical
      and clinical data and program results, or any other information or data
      acquired or generated by AMRI as a result of this Agreement or from
      performance of the Services to be rendered hereunder (“SPRI Confidential
      Information”), AMRI agrees that it will not, and will not permit any of
      its employees, consultants, or representatives to, use said information
      other than for the purposes of this Agreement, it will not, and will not
      permit any of its employees, consultants, or representatives to, disclose
      any of said information to a third party except as is required pursuant to
      the purposes of this Agreement, and it will not, and will not permit any
      of its employees, consultants, or representatives to, publish or submit
      for publication said information without SPRI’s prior
      approval.  AMRI shall only disclose SPRI Confidential
      Information to AMRI’s employees, consultants or representatives who have
      entered into written confidentiality and non-use agreements with AMRI
      having terms substantially similar to those set forth in this
      Agreement.

            

    

    

    
      	
               
      

            	
              2.

            	
              AMRI
      agrees to utilize all reasonable efforts to create confidentiality
      firewalls between different groups of its employees working on different
      Projects under this Agreement so that SPRI Confidential Information from
      one Project is not disclosed to AMRI employees working on a different
      Project.

            

    

    

    
      	
               
      

            	
              3.

            	
              AMRI’s
      obligation with regard to confidential information, which is a Trade
      Secret (as defined herein) shall continue at all times from and after the
      date of this Agreement, and with regard to confidential information which
      is not a Trade Secret, shall continue for a period of five (5) years from
      the date of termination of this Agreement.  For purposes of
      this Agreement, the term “Trade Secrets” shall
      mean:  information including, but not limited to, technical or
      nontechnical data, a formula pattern, compilation, program, device,
      method, technique, drawing, process, financial data, or list of actual or
      potential customers or suppliers
which:

            

    

    

    
      	
               
      

            	
              (i)

            	
              Derives
      economic value, actual or potential, from not being generally known to
      other persons who can obtain economic value from its disclosure or use;
      and

            

    

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    
      	
               
      

            	
              (ii)

            	
              Is
      the subject of efforts that are reasonable under the circumstances to
      maintain its secrecy or
confidentiality.

            

    

    

    SPRI
shall promptly identify the information that SPRI considers Trade Secrets in
order for AMRI to perform the obligations hereunder.  If information
is not designated by SPRI as a Trade Secret upon disclosure, it shall be treated
by AMRI as confidential.

    

    
      	
               
      

            	
              4.

            	
              The
      foregoing obligations shall not apply to information which is or lawfully
      becomes generally available to the public through no fault of AMRI, which
      is lawfully acquired from third parties who have a right to disclose such
      information, or which by mutual agreement is released from a confidential
      status.

            

    

    

    
      	
              E.

            	
              Term and
      Termination:

            

    

    

    
      	
               
      

            	
              1.

            	
              This
      Agreement shall commence on the date first set forth above and shall
      terminate after three (3) years, unless earlier terminated by either party
      hereto (the “Term”).  The Term of this Agreement may be extended
      by mutual written agreement of the
parties.

            

    

    

    
      	
               
      

            	
              2.

            	
              The
      representations and warranties contained in this Agreement (including the
      recitals hereto), as well as those rights and/or obligations contained in
      the terms of this Agreement which by their intent or meaning have validity
      beyond the term hereof, including without limitation Sections D, I, and
      K.3. hereof, shall survive the expiration or termination of this
      Agreement.

            

    

    

    
      	
               
      

            	
              3.

            	
              This
      Agreement may be terminated prior to the expiration of the term only under
      the following Conditions:

            

    

    

    
      	
               
      

            	
              a)

            	
              By
      either party, if the other party materially breaches any of the covenants
      and agreements under this Agreement, upon thirty (30) days written notice
      to the other party.

            

    

    

    
      	
               
      

            	
              b)

            	
              By
      SPRI, if AMRI is substantially unable to perform assigned duties hereunder
      whether due to sickness, disability or incapacity, or any other reason,
      upon thirty (30) days written notice to
AMRI.

            

    

    

    
      	
               
      

            	
              c)

            	
              By
      AMRI, if SPRI fails to pay fees and/or fails to reimburse AMRI for
      reimbursable expenses as provided in Section F.2. upon thirty (30) days
      written notice to SPRI.

            

    

    

    
      	
               
      

            	
              d)

            	
              [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] may terminate this
      Agreement or any Project [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] upon
      written notice to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] under the
      [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/]:

            

    

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    
      	
               
      

            	
              (i)

            	
              if
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] desires to terminate the
      Agreement or any Project [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] and
      wind-down any Projects, [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] shall
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] the then current number of
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] until the total number of
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] have been [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]; or

            

    

     

    
      	
               
      

            	
              (ii)

            	
              if
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] desires to terminate the
      Agreement or any Project [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], then
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] shall [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] the
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] charges [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] under the [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
      as described [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] using the
      [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/].

            

    

    

    
      [CONFIDENTIAL
TREATMENT REQUESTED BY AMRI – 02]

    

    

    
      	
               
      

            	
              4.

            	
              If
      any Research Project Appendix entered into prior to the end of the Term
      shall have an expiration date after the last day of the Term, then
      nothwithstanding the end of the Term set forth in this Section E, this
      Agreement shall remain in full force and effect until the expiration of
      such Research Project Appendix and references herein to “Term” shall refer
      to the period ending with the expiration date of such Research Project
      Appendix, but only with respect to such Research Project Appendix and the
      Services described therein.

            

    

    

    
      	
              F.

            	
              Communications and
      Payments:

            

    

    

    
      	
               
      

            	
              1.

            	
              Communications:  All
      communications associated with this Agreement shall be by first class mail
      or courier, addressed to the respective parties as
  follows:

            

    

     

    
      
        
          	
                  To
      AMRI:

                	
                  Chief
      Financial Officer

                
	 
      	
                  Albany
      Molecular Research, Inc

                
	 
      	
                  21
      Corporate Circle

                
	 
      	
                  Albany,
      New York 12203-5154

                
	 
      	 
      
	
                  With
      a copy to:

                	
                  Director,
      Contracts, Licensing & Legal Affairs

                
	
                   
      

                	
                  Albany
      Molecular Research, Inc

                
	 
      	
                  21
      Corporate Circle

                
	 
      	
                  Albany,
      New York 12203-5154

                
	 
      	 
      
	
                  To
      SPRI:

                	
                  Vice
      President, Chemistry

                
	 
      	
                  Schering-Plough
      Research Institute

                
	 
      	
                  2015
      Galloping Hill Road

                
	 
      	
                  Kenilworth,
      New
Jersey  07033

                

        

      

    

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    
      
        	
                With
      a copy to:

              	
                Director,
      Discovery Collaborations

              
	 
      	
                Schering-Plough
      Research Institute

              
	 
      	
                2015
      Galloping Hill Road

              
	 
      	
                Kenilworth,
      NJ  07033

              

      

    

    

    
      	
               
      

            	
              2.

            	
              Payments:  In
      consideration of the Services that are performed by AMRI under this
      Agreement, SPRI will pay AMRI at the following [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] for work conducted pursuant to agreed upon [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]:

            

    

    

    
      	
               
      

            	
              a)

            	
              Fees:  The
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] rate per FTE is outlined in the
      table below.  When the total number of FTEs employed under this
      Agreement triggers [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] in the
      applicable FTE rate below, then that [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] shall [/*[CONFIDENTIAL TREATMENT
    REQUESTED]*/].

            

    

    

    
      
        
          
            
              
                
                  	
                          Number of 

                          FTEs

                        	 	
                          [/*[CONFIDENTIAL

                          TREATMENT

                          REQUESTED]*/]

                          Rate

                          Per FTE

                        	 	
                          Estimated [/*[CONFIDENTIAL

                          TREATMENT REQUESTED]*/]

                          Expenses per [/*[CONFIDENTIAL

                          TREATMENT REQUESTED]*/]

                          per FTE

                        
	
                          [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        	 	
                          $[/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        	 	
                          $[/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        
	
                          [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        	 	
                          $[/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        	 	
                          $[/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        
	
                          [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        	 	
                          $[/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/]

                        	 	
                          $[/*[CONFIDENTIAL
      TREATMENT
REQUESTED]*/]

                        

                

              

            

          

        

      

    

    

    Payment
to AMRI by SPRI shall not be later than [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
of an appropriately documented and undisputed invoice.  The above FTE
rate may be adjusted [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] by a percentage
that is [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] in the [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] for the [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] region
from the prior year, as reported by the [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/].  Such [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
adjustments shall not exceed [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/].

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    
      	
               
      

            	
              b)

            	
              Reimbursed
      Expenses:  SPRI will reimburse AMRI for [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] reasonable and necessary expenses [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] while [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
      pursuant to this Agreement and which are in accordance with SPRI’s
      Reimbursement Policy, a copy of which is attached hereto as Appendix 2.  AMRI shall submit
      signed requests with each invoice for reimbursement on AMRI’s letterhead
      or other identifying stationery (“Expense Reports”), accompanied by a
      reasonably detailed list of expenses.  [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] reimbursable expenses shall not [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] an aggregate total of [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] multiplied by the [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
      working on SPRI projects without prior authorization from SPRI, such
      authorization shall not be unreasonably delayed or
      withheld.  Reasonable and necessary expenses shall include:
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] used directly in the Projects;
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], etc.); [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] used directly in the Projects; [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] used in the Projects (upon authorization by SPRI
      to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]; and, [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] requested by SPRI.  AMRI will not
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], nor [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] in the normal course of performing
  Services.

            

    

    

    
      	
               
      

            	
              [CONFIDENTIAL
      TREATMENT REQUESTED BY AMRI –
03]

            

    

    

    
      	
              G.

            	
              Assignment:

            

    

    

    
      	
               

            	
              Neither
      party shall have the right to assign this Agreement or any of the rights
      or obligations hereunder without the prior written consent of the other
      party, except that either party may assign this Agreement to an affiliate
      without such prior consent.

            

    

    

    
      	
              H.

            	
              Entire
      Agreement:

            

    

    

    
      	
               
      

            	
              1.

            	
              This
      Agreement represents the entire agreement of the parties with respect to
      the subject matter hereof and supersedes all prior understandings and
      agreements with respect thereto.

            

    

    

    
      	
               
      

            	
              2.

            	
              No
      change or modification of the provisions of this Agreement shall be
      effective unless it is in writing and signed by a duly authorized officer
      of AMRI and SPRI.

            

    

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    
      	
              I.

            	
              Project Ownership and
      Retention of Records:

            

    

     

    
      	
               
      

            	
              1.

            	
              Subject to SPRI satisfying its obligations under
      C.3. and F.2., all [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] of
      any kind and [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] supplied to AMRI
      from SPRI or [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] the Services
      performed hereunder shall be the sole and exclusive property of
      SPRI.  Any [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], whether
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] or not that may [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] above described or [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] shall be the sole and exclusive property of SPRI, and AMRI
      agrees to assign or cause to be assigned all rights thereto to
      SPRI.  AMRI and its employees agree to cooperate with SPRI in
      taking all steps which SPRI believes reasonably necessary or desirable to
      secure its rights on this property at SPRI’s cost.  In
      consideration of the foregoing, SPRI agrees to grant to AMRI
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] to practice any [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] solely generated by AMRI that are specifically
      directed to AMRI’s [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], to the extent
      such technology has [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]; provided,
      however, that such use by AMRI under this [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] shall not [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] any
      program or product [/*[CONFIDENTIAL TREATMENT
    REQUESTED]*/].

            

    

    

    
      	
               
      

            	
              [CONFIDENTIAL
      TREATMENT REQUESTED BY AMRI –
04]

            

    

    

    
      
      

    

    
      	
               
      

            	
              2.

            	
              During
      the term of this Agreement, AMRI shall maintain all written materials and
      all other data obtained or generated by AMRI in the course of providing
      the Services performed under this Agreement in a secure area reasonably
      protected from fire, theft and destruction.  At the expiration
      or termination of this Agreement, all written materials and other data and
      information obtained or generated by AMRI in the course of providing the
      Services will be retained by AMRI in accordance with Section B.1.j or, at
      SPRI’s option, be (a) delivered to SPRI or its designee in such form as is
      then currently in the possession of AMRI, (b) retained by AMRI for SPRI
      for a period of time mutually agreed upon by the parties, or (c) disposed
      of, at the direction and written request of SPRI, unless such materials
      are otherwise required to be stored or maintained by AMRI as a matter of
      law or regulation.

            

    

    

    
      	
              J.

            	
              Safety and
      Environmental:

            

    

    

    
      	 	
              In
      carrying out its responsibilities under this Agreement, AMRI agrees to
      assure that the Services are conducted in compliance with any applicable
      SPRI protocols and/or specifications of which AMRI is reasonably advised
      in a timely manner and in compliance with all applicable laws, rules, and
      regulations, including, but not limited to, the U.S. Food, Drug and
      Cosmetic Act and the regulations promulgated pursuant
      thereto.  Also included is compliance with all relevant
      environmental regulations in force at the U.S. Federal, State, and Local
      levels.

            

    

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    
      	
              K.

            	
              Miscellaneous:

            

    

    

    
      	
               
      

            	
              1.

            	
              AMRI
      represents and warrants that it will render the Services hereunder in
      accordance with prevailing high professional standards and will make all
      reasonable efforts to produce consistently high levels of accuracy and
      expertise and to meet timetables set forth under this Agreement for
      completion of Services.  AMRI further represents and warrants
      that personnel assigned to perform Services under this Agreement shall
      have the skills necessary to efficiently perform such Services and shall
      produce chemicals, data, and/or reports, as the case may be, in a form and
      of a quality suitable to SPRI and that for each group of five (5) AMRI
      employees providing Services hereunder, at least two (2) employees shall
      have a doctorate degree in the chemistry
field.

            

    

    

    
      	
               
      

            	
              2.

            	
              AMRI
      will endeavor with all reasonable effort to conform to its obligations
      identified herein.  Although no delays or limits beyond AMRI’s reasonable control in
      performing any Projects are expected, if such delays or limits are
      encountered, AMRI will promptly notify SPRI accordingly and AMRI shall use
      all reasonable efforts to eliminate or minimize such delays or
      limits.  SPRI agrees to accommodate any reasonable change in
      timetables as a result of such delays that AMRI cannot reasonably
      eliminate or minimize, provided the Projects have been proceeding to
      SPRI’s satisfaction.

            

    

    

    
      	
               
      

            	
              3.

            	
              AMRI
      will further permit SPRI to audit AMRI’s relevant, non-financial records
      during and after the term of this Agreement, but not more than once per
      calendar year, solely to permit SPRI to confirm that the Services are or
      have been performed in compliance with applicable laws and
      regulations.

            

    

    

    
      	
               
      

            	
              4.

            	
              AMRI
      is an independent company and nothing in this Agreement shall be construed
      to create a partnership, joint venture, or employment relationship between
      the parties.

            

    

    

    
      	
               
      

            	
              5.

            	
              AMRI,
      on behalf of itself and its employees, agents, subcontractors, and
      affiliates agrees not to use the name of SPRI or any of its employees,
      agents, affiliates, or subsidiaries, or reference any of their products,
      in any publicity, advertising, or other publication without SPRI’s prior
      written approval.

            

    

    

    
      	
               
      

            	
              6.

            	
              If
      any provision hereof shall be determined to be invalid or unenforceable,
      such determination shall not affect the validity of the other provisions
      of this Agreement.

            

    

    

    
      	
               
      

            	
              7.

            	
              This
      Agreement shall be governed in accordance with the laws of the State of
      New York.

            

    

    

    
      	
               
      

            	
              8.

            	
              Waiver
      by either party or the failure by either party to claim a breach of any
      provision of this Agreement shall not be deemed to constitute a waiver or
      estoppel with respect to any subsequent breach of any provision
      hereof.

            

    

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    
      	
               
      

            	
              9.

            	
              [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] agrees to assume the liability for injury or
      damage caused by [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] provided by
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], provided such [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] is not caused by [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/], intentional activity, or failure to meet required
      specifications or breach of any applicable federal, state, or local
      law.  [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] to indemnify,
      defend, and hold harmless [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] from
      any and all liability arising out of such [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] assessed against it.  [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/] agrees to assume the liability for [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] caused by its [/*[CONFIDENTIAL TREATMENT
      REQUESTED]*/], provided such [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] is
      not caused by [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], intentional
      activity, or failure to meet required specifications or breach of any
      applicable federal, state, or local law.  [/*[CONFIDENTIAL
      TREATMENT REQUESTED]*/] agrees to indemnify, defend and hold harmless
      [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] from any and all liability
      arising out of said [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], including
      but not limited to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] assessed
      against it.

            

    

    

    [CONFIDENTIAL
TREATMENT REQUESTED BY AMRI – 05]

    

    IN WITNESS WHEREOF, the
parties have caused this Agreement to be executed by their duly authorized
representatives.

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          	
                                  Albany
      Molecular Research, Inc.

                                	 	
                                  SCHERING
      CORPORATION,

                                  acting
      through its Schering-Plough

                                  Research
      Institute division

                                
	 
      	 
      	 	 
      	 
      
	
                                  By:

                                	
                                  /s/
      Eric W. Smart

                                	 	
                                  By:

                                	
                                  Cecil
      B. Pickett

                                
	 
      	 
      	 	 
      	 
      
	 
      	 
      	 	 
      	
                                  an
      authorized representative

                                
	 
      	 
      	 	 
      	
                                  of
      Schering-Plough Research Institute

                                
	 
      	 
      	 	 
      	 
      
	
                                  Name:

                                	
                                  Eric
      W. Smart

                                	 	
                                  Name:

                                	
                                  Cecil
      B. Pickett, Ph.D.

                                
	 
      	 
      	 	 
      	 
      
	
                                  Title:

                                	
                                  VP,
      Business Development

                                	 	
                                  Title:

                                	
                                  President,
      SPRI

                                
	 
      	 
      	 	 
      	 
      
	
                                  Date:

                                	
                                  January
      10, 2006

                                	 	
                                  Date:

                                	
                                  January
      13,
2006

                                

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    APPENDIX
1

    

    FORM OF
RESEARCH PROJECT APPENDIX

    

    This
Research Project Appendix is entered into by Schering Corporation, acting
through its Schering-Plough Research Institute division (“SPRI”) and Albany
Molecular Research, Inc. (“AMRI”) as of the Effective Date of the Agreement
(defined below).  This Research Project Appendix is entered into
pursuant to and is subject to the terms of  that certain
Research/Manufacturing Agreement dated January 13, 2006 (the “Agreement”) by and
between SPRI and AMRI.

     

    This
Research Project Appendix sets forth the Services to be performed by AMRI
(including deliverables to be provided to SPRI in connection therewith), the
timing for the Project, the cost and payment schedule, and any individuals
designated to have management responsibility for the Project or otherwise
required to perform the Services.  NO TERM, CONDITION OR OTHER
PROVISION OF THIS RESEARCH PROJECT APPENDIX (INCLUDING ANY ATTACHMENTS) SHALL
SUPERSEDE ANY TERM, CONDITION OR OTHER PROVISION OF THE AGREEMENT, AND WITH
RESPECT TO ANY INCONSISTENCY, CONFLICT OR AMBIGUITY, THE AGREEMENT, INCLUDING
APPENDIX 2, SHALL CONTROL.  ANY PROVISION OF THIS RESEARCH PROJECT
APPENDIX (INCLUDING ANY ATTACHMENTS) WHICH CONFLICTS WITH ANY TERM OF THE
AGREEMENT IS VOID AND OF NO FORCE OR EFFECT WHATSOEVER, NOTWITHSTANDING THAT
THIS RESEARCH PROJECT APPENDIX MAY BE EXECUTED AND DELIVERED AFTER THE EXECUTION
AND DELIVERY OF THE AGREEMENT.  Subject to the foregoing, this
Research Project Appendix is incorporated into the Agreement and expressly made
a part thereof.

    

    All
initially capitalized terms used in this Appendix but not defined in this
Appendix shall have the meanings given in the Agreement.

    

    
      	
              Purpose:

            	
              AMRI
      will provide up [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Full-Time
      Equivalent (“FTE”) scientists (to the extent requested by SPRI) for
      medicinal chemistry services and synthesis services of compounds as
      described below or as may be amended from time to time in subsequent
      writings signed by both parties.  A detailed description of the
      Project and Services is set forth in Attachment 1, which is incorporated
      herein by reference.

            

    

    

    [CONFIDENTIAL
TREATMENT REQUESTED BY AMRI – 06]

    

    
      	
              Term:

            	
              Appendix
      1 is in effect beginning on the Effective Date of the Agreement and
      continues in effect until December 31, 2006 or earlier terminated by
      either party pursuant to Article E of the Agreement.
  

            

    

    

    Additional
FTE scientists or the use of other part-time support, such as computational
services or non-routine analytical services shall be subject to separate written
agreement.

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    AMRI
personnel resources:

    

    AMRI
shall make available FTE scientists as follows:

    

    [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] FTEs [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] on the
Effective Date of the Agreement.

    

    [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] FTEs on or about February 1, 2006.

    

    [CONFIDENTIAL
TREATMENT REQUESTED BY AMRI – 07]

     

    
      	
              I.

            	
              AMRI
      FTE Assignments and Deliverables 

            

    

     

    
      	
               
      

            	
              A.

            	
              AMRI
      shall prepare compounds for biological screening and other compounds,
      scaffolds, and reference compounds as SPRI directs AMRI during the term of
      this Research Project Appendix. 

            

    

    

    
      	
               
      

            	
              B.

            	
              AMRI
      shall provide Certificates of Analysis for all compounds, including at
      least one proton NMR, mass spectrum, and other characterization as may be
      required and mutually agreed to by the parties. AMRI shall conduct
      analyses on the compounds pursuant to A) above utilizing appropriate
      chromatographic and spectroscopic techniques.

            

    

    

    
      	
               
      

            	
              C.

            	
              AMRI
      shall prepare written reports on a periodic basis to SPRI detailing the
      progress of the research hereunder.

            

    

    

    
      	
              II. 

            	
              SPRI
      Resources and Materials

            

    

    

    SPRI
shall provide to AMRI compound formulae, samples, synthetic methodology,
spectral data, and literature references as SPRI deems appropriate and if
available.  SPRI further reserves the right to supply AMRI with raw
materials and reagents.

    

    
      	
              III. 

            	
              Invoicing
      and Payment

            

    

    

    AMRI
shall invoice SPRI [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] for [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] devoted to this Project at the rate specified in Section
F.2.a of the Agreement, and SPRI shall pay each invoice as provided for pursuant
to Section F.2 of the Agreement.  

    

    [CONFIDENTIAL
TREATMENT REQUESTED BY AMRI – 08]

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    All terms
and conditions of the Agreement shall remain in full force and
effect.  

    

    NO WORK
SHALL BE PERFORMED HEREUNDER UNTIL BOTH PARTIES HAVE EXECUTED THIS RESEARCH
PROJECT APPENDIX.  VERBAL AUTHORIZATION AND/OR INSTRUCTIONS TO
COMMENCE WORK (INCLUDING ANY SERVICES) SHALL BE OF NO EFFECT, AND ANY WORK OR
SERVICES PERFORMED BY AMRI PRIOR TO EXECUTION OF THIS RESEARCH PROJECT APPENDIX
BY BOTH PARTIES SHALL BE AT AMRI’S SOLE RISK AND EXPENSE.

     

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

     

    In
Witness Whereof, the parties have duly executed and delivered to each other this
Appendix 1.

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      	
                                              Albany Molecular Research, Inc.

                                            	 	
                                              SCHERING
      CORPORATION,

                                            
	 
      	 
      	 	
                                              acting
      through its Schering-Plough

                                            
	 
      	 
      	 	
                                              Research
      Institute division

                                            
	 
      	 
      	 	 
      	 
      
	
                                              By:

                                            	
                                              /s/
      Eric W. Smart

                                            	 	
                                              By:

                                            	
                                              /s/
      Cecil B. Pickett

                                            
	 	 	 	 	 
	 
      	 
      	 	 
      	
                                              an
      authorized representative of

                                            
	 
      	 
      	 	 
      	
                                              Schering-Plough
      Research Institute

                                            
	 	 	 	 	 
	
                                              Name:

                                            	
                                              Eric
      W. Smart

                                            	 	
                                              Name:

                                            	
                                              Cecil
      B. Pickett, Ph.D.

                                            
	 
      	 
      	 	 
      	 
      
	
                                              Title:

                                            	
                                              VP
      Business Development

                                            	 	
                                              Title:

                                            	
                                              President,
      SPRI

                                            
	 
      	 
      	 	 
      	 
      
	
                                              Date:

                                            	
                                              January
      10, 2006

                                            	 	
                                              Date:

                                            	
                                              January
      13,
2006

                                            

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    APPENDIX 2

    

    REIMBURSEMENT POLICY

    

    In accordance with SPRI’s standard policies and
procedures, the following are types of expenses for which SPRI will not
reimburse, unless expressly agreed to in a prior writing by the
parties:

    

    
      	
              -

            	
              Commuting expenses to and/or from your place of
      business or residence (excluding transportation costs to and/or from the
      airport for SPRI-requested
business)

            

    

    

    
      	
              -

            	
              Add-on costs with respect to outside services,
      including but not limited to mark-up for the work product of outside
      professionals, including but not limited to
    freelancers

            

    

    

    
      	
              -

            	
              Meals (except during travel periods in connection
      with the services rendered to SPRI).  For this exception,
      reasonableness shall be measured at US rates of $50 for dinner and $25
      each for breakfast and lunch, tax and
      tip included in all cases

            

    

    

    
      	
              -

            	
              Administrative and/or overhead percentages
      

            

    

     

    
      	
              -

            	
              Agency presentations for new
      business

            

    

     

    
      	
              -

            	
              Business-class air travel.  Business-class air travel
      is only reimbursable if approved in writing in advance by the area Vice
      President

            

    

    

    
      The following types of expenses are not
reimbursable:

          

    

    
      	
              -

            	
              First-class air travel
  

            

    

     

    
      	
              -

            	
              Mark-up on any out-of-pocket
      expenses

            

    

     

    
      	
              -

            	
              Travel
time

            

    

     

    
      	
              -

            	
              Gifts to SPRI’s
      employees

            

    

        

    
      	
              -

            	
              Entertainment of SPRI’s
      employees

            

    

     

    This list
sets forth the major items for which SPRI will not reimburse you and is meant to
be merely illustrative and not exhaustive. All your expenses shall be reviewed
with respect to the reasonableness of such expenses.

     

    
      
        
        

      

      
        16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]